Cigna's Specialty Pharmacy Leadership Expected to Drive Long-Term EPS Growth, Analyst Says
Cigna's Specialty Pharmacy Leadership Expected to Drive Long-Term EPS Growth, Analyst Says
Piper Sandler has initiated coverage on Cigna Corporation (NYSE:CI), a diversified managed care and healthcare delivery organization specializing in commercial insurance markets and pharmacy services.
派傑投資已開始覆蓋範圍涵蓋商業保險市場和藥房服務的綜合醫療保健和醫療保障提供者Cigna Corporation（NYSE：CI）的評級。
The analyst writes, "We believe Cigna has a unique and defensible leadership position in the fast-growing specialty pharmacy market which, together with the company's insurance segment and core PBM business, should support LT-adjusted EPS growth at a 10-14% CAGR."
分析師寫道：“我們認爲Cigna在快速增長的特殊藥房市場上擁有獨特而具有競爭力的領導地位，此外，公司的保險業務和核心PBM業務應支持LT調整後的EPS增長率在10-14%之間。”
Related: Cigna Crushes Q1 Estimates: Revenue Soars With Evernorth's Explosive Growth.
相關新聞: 吉利德的 Trodelvy 在普通膀胱癌最常見類型的後期研究中未能達到主要目標。Cigna衝破Q1預期：隨着Evernorth的爆炸式增長，營業收入飆升。
The company's Cigna Healthcare and Evernorth Health Services businesses complement one another and empower Cigna to continue delivering premium adjusted EPS growth against the LT target of 10-14% per year, the Piper analyst writes.
該公司的Cigna Healthcare和Evernorth Health Services業務互補，並使Cigna能夠繼續實現針對每年10-14%的LT目標的優質調整後的EPS增長，Piper分析師寫道。
Cigna grew adjusted EPS at a 13%+ CAGR from 2013-2023, and the company is expected to maintain its track record of consistent execution against industry-leading earnings growth targets over the next decade.
Cigna從2013年至2023年以13%+的CAGR增長了調整後的EPS，預計未來十年公司將保持持續執行行業領先盈利增長目標的記錄。
Piper adds, "We believe CI will focus on organic earnings growth until we know the outcome of the 2024 presidential election and get a better understanding of the antitrust/ MA regime for the next 4 years."
Piper補充道：“我們認爲（CI）將專注於有機盈利增長，直到我們知道2024年總統大選的結果，並更好地了解未來4年的反壟斷/ MA制度。”
Piper initiates with an Overweight rating and a price target of $400.
Piper發起超配評級，並將目標價定爲400美元。
A 12.5x multiple is appropriate as it assigns an in-line/slight-premium multiple to the comp group, which Piper writes is justified by Cigna's above-average EPS CAGR.
12.5倍的倍數是適當的，因爲它爲競爭集團分配了一個與之相符的略高倍數，Piper寫道，這是由Cigna高於平均EPS CAGR所證明的。
The analyst also writes that selling the medicare advantage business to HCSC will be a positive catalyst for Cigna when it closes in the first quarter of 2025.
該分析師還寫道，將醫療保險業務出售給HCSC將成爲Cigna的積極催化劑，該交易預計在2025年第一季度結束。
Piper says Cigna's strong position in the $400 billion specialty market is encouraging. While many are tackling the drug pricing crisis, Cigna is at the forefront.
Piper表示，Cigna在4000億美元的特殊市場中的強勁地位令人鼓舞。雖然許多人正在解決藥品定價危機，但Cigna處於最前沿。
Specialty services drive growth for Evernorth, which is supported by Cigna's transparent PBM business. We are confident in Evernorth's 5-8% long-term growth forecast.
特殊服務推動Evernorth的增長，其由Cigna透明的PBM業務支持。我們對Evernorth的長期增長預測爲5-8%充滿信心。
Price Action: CI shares are down 0.41% at $337.41 at the last check on Wednesday.
價格行動：CI股價週三最後一次檢查時下跌0.41％至337.41美元。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。